Adicet Bio/ACET

$2.45

1.24%
-
1D1W1MYTD1YMAX

About Adicet Bio

Adicet Bio, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing allogeneic gamma delta T cell therapies for cancer. The Company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. Its product candidate, ADI-001, is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20 used for the treatment of relapsed or refractory B-cell non-Hodgkins lymphoma (NHL). Its pipeline also includes ADI-925, which is a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Its pipeline also includes additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Ticker

ACET

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Chen Schor

Employees

132

Headquarters

Boston, United States

Adicet Bio Metrics

BasicAdvanced
$173.3M
Market cap
-
P/E ratio
-$3.33
EPS
1.89
Beta
-
Dividend rate

What the Analysts think about Adicet Bio

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
372.24% upside
High $27.00
Low $5.00
$2.45
Current price
$11.57
Average price target

Adicet Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-49.8M
53.7%
Profit margin
0%
-

Adicet Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 57.33%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.72
-$0.72
-$0.75
-$1.16
-
Expected
-$0.28
-$0.69
-$0.68
-$0.74
-$0.69
Surprise
158.06%
4.76%
10.04%
57.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Adicet Bio stock

Buy or sell Adicet Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing